Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • tonup69
    Associate Professor
    • Apr 2011
    • 20

    TOPHAT2 vs STAR and CUFFMERGE vs CUFFCOMPARE: CASE STUDY

    I've been busy. I'm still analyzing and re-analyzing some fly data that we are getting ready for publication and I found some interesting caveats I thought I would share with the SEQanswers community. Please keep in mind that all of these analyses were done on our local install of GALAXY - I don't have time for command line foolery and these are the same programs with the same options.

    Basic Study Design:
    UAS-Gene X (3 tech replicate)
    Repo-GAL4>UAS-Gene X (3 replicates)
    C155-GAL4>UAS-Gene X (3 replicates)

    Samples were run on an Ion Proton machine here at the Molecular Resource Center.

    Pipeline for Analysis: Tuxedo (Cuff-etc...)

    Mapping:
    I used TOPHAT2 for mapping with a reference sequence and GTF file for flies. Based on discussions here, I also used RNA-STAR. I got approximately 50% mapped reads (average 30M reads to start) using TOPHAT2 and 80% mapped reads with RNA-STAR. Sounds great, right? Well, along the way I found some things that are disturbing.

    Cuffmerge vs Cuffcompare:
    I realize these two programs are not exactly the same, but they should be similar, right? They both produce a reference GTF file for Cuffdiff to use to determine differential gene expression. Here are JUST the RNA-STAR mapped results using the classic-fpkm option.





    Looks like Cuffmerge produced more significantly different genes per group across all groups, but the numbers are not crazy different.

    Looking closer at just genes that were unique to Repo expression or C155 expression, I was surprised to find that there are rather large differences. in fact only a few genes are the same for both Cuffmerge and Cuffcompare.





    There were bumps along the road here and things I would like to improve with this pipeline, but what is most disturbing is this huge difference in both mapping and GTF file production depending on which option you choose. I am going to try to use DeSeq and EdgR (which are not working on our install right now). May show the output for that as well just for the record.

    Its a good example of "be careful what you believe" in bioinformatic analysis. This is why we do experiments to VALIDATE even RNAseq data.
  • mastal
    Senior Member
    • Mar 2009
    • 666

    #2
    You should probably use DESeq2 instead of DESeq.

    I think the statisticians would probably say that the reason you get results like that is because even 3 replicates is not really a large sample.

    Comment

    • tonup69
      Associate Professor
      • Apr 2011
      • 20

      #3
      Originally posted by mastal View Post
      You should probably use DESeq2 instead of DESeq.

      I think the statisticians would probably say that the reason you get results like that is because even 3 replicates is not really a large sample.
      I would agree if these were human or mouse samples, but these are iosgenic fly stocks being used and all of the transgenes were placed into the same w1118 background. We usually get very tight statistics even for behavior studies in flies.

      Comment

      • tonup69
        Associate Professor
        • Apr 2011
        • 20

        #4
        Also, this is the SAME mapping data using Cuffdiff with the same settings in both cases. It is only Cuffcompare vs Cuffmerge that is different here.

        Comment

        • Brian Bushnell
          Super Moderator
          • Jan 2014
          • 2709

          #5
          Well gosh, this sounds like a perfect case to bring in a third aligner as a tie-breaker! Not all RNA-seq aligners play nice with reads containing short indels, you know. But I happen to know that BBMap does

          As far as the post-mapping analysis part goes... when tool X and tool Y give different results, I would place much more faith in the tool that does not start with "Cuff".

          Comment

          • gringer
            David Eccles (gringer)
            • May 2011
            • 845

            #6
            As far as the post-mapping analysis part goes... when tool X and tool Y give different results, I would place much more faith in the tool that does not start with "Cuff".
            Indeed. This is especially so when the group that developed Cufflinks has released another program that supersedes it:

            Nonetheless, StringTie consistently outperforms Cufflinks by a substantial amount, as shown below on four real data sets: GSM981256, GSM981244, GSM984609, and SRP041943


            The same applies to Tophat2:

            HISAT2 is a successor to both HISAT and TopHat2. We recommend that HISAT and TopHat2 users switch to HISAT2.


            It surprises me that you are aware of STAR, but not of HISAT2 and StringTie.

            FWIW, the authors of DESeq have also indicated that DESeq2 is better:

            Well, yes, it is intended. DESeq had a rather ugly hack to ensure type-I error control, which cost a lot of power, and fixing this was the core aim of the development of DESeq2.
            Application of sequencing to RNA analysis (RNA-Seq, whole transcriptome, SAGE, expression analysis, novel organism mining, splice variants)
            Last edited by gringer; 02-19-2016, 02:43 AM.

            Comment

            • tonup69
              Associate Professor
              • Apr 2011
              • 20

              #7
              Other programs....

              Well, as usual, analysis of sequence data is a moving target. Thanks for the other program options - I will look into these with our local Bioinformatics person who maintains our server.

              That being said, I am not looking for perfection. I would like to find a set of significantly dysregulated transcripts which can be validated biologically. It is my feeling that even the Tuxedo pipeline should be able to do to that!

              I'll try to use what I have now and see if any of this is true (i.e. these transcripts really change significantly by qRT-PCR). We will go from there.

              LTR

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM
              • SEQadmin2
                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                by SEQadmin2



                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                07-08-2026, 05:17 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, 07-24-2026, 12:17 PM
              0 responses
              20 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-23-2026, 11:41 AM
              0 responses
              19 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-20-2026, 11:10 AM
              0 responses
              26 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-13-2026, 10:26 AM
              0 responses
              38 views
              0 reactions
              Last Post SEQadmin2  
              Working...